Active substance

Results for the substance avapritinib

5 results

About this active substance

Avapritinib is a selective kinase inhibitor used in the treatment of advanced or metastatic gastrointestinal stromal tumors (GIST), particularly those with rare mutations in the PDGFRA gene. It works by blocking the activity of abnormal kinases, inhibiting tumor cell growth and proliferation.

Avapritinib is administered orally, usually once daily, with the dose adjusted based on patient response and tolerability. It is indicated for patients with GIST who are unresponsive to other therapies or have specific mutations that make tumors resistant to standard treatments.

Common side effects include nausea, vomiting, fatigue, peripheral edema, and anemia. In rare cases, severe adverse reactions such as bleeding, liver function impairment, or cognitive disturbances may occur. Regular monitoring of hematological and metabolic parameters is essential during treatment.

Avapritinib represents an innovative therapeutic option for patients with advanced GIST, offering a targeted approach to disease control and improved quality of life.